Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
As of 03:30PM EST. Market open.
| Previous Close | 103.46 |
| Open | 103.22 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 102.48 - 103.79 |
| 52 Week Range | 72.88 - 115.49 |
| Volume | |
| Avg. Volume | 9,149,380 |
| Market Cap | 261.729B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 17.12 |
| EPS (TTM) | 6.03 |
| Earnings Date | Apr 27, 2023 |
| Forward Dividend & Yield | 2.92 (2.73%) |
| Ex-Dividend Date | Mar 14, 2023 |
| 1y Target Est | 117.52 |
- Yahoo Finance
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
- Zacks
Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J., February 03, 2023--Merck’s KEYTRUDA Plus Chemotherapy Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
© 2023 Yahoo. All rights reserved.
